Law360 recently quoted Blackwell Burke P.A. partner Peter J. Goss in an article discussing the first lawsuit filed against the New England Compounding Center (NECC). That center made the steroids implicated in the current 12-state fungal meningitis outbreak. Mr. Goss described how this first plaintiff’s and future plaintiffs’ ability to collect damages from NECC would be limited by the pharmacy’s capitalization and insurance. He further explained that NECC’s insurance coverage is likely much lower than it would be for either branded or generic pharmaceutical manufacturers. The article, “Meningitis Plaintiffs Face Uphill Battle If Pharmacy Fails,” is available here.
Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented major pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss, who has won several published Daubert decisions, often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence and legal developments of interest to FDA-regulated industries.
Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for numerous Fortune 500 companies. The firm has extensive experience in class action defense, commercial litigation, food industry defense, labor and employment, and products liability. The firm has represented corporate clients in practically every jurisdiction in the country, as well as several foreign countries.